Welcome to our dedicated page for CONMED SEC filings (Ticker: CNMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CONMED Corporation filings document the regulatory record for a medical technology company with common stock listed on the NYSE under the symbol CNMD. Its Form 8-K reports cover quarterly and annual operating results, investor presentations furnished under Regulation FD, finance leadership changes, and portfolio actions involving gastroenterology products and distribution agreements.
The company’s proxy materials disclose board matters, annual meeting voting, executive compensation, equity awards, and related governance information. CONMED’s filing record also identifies its capital stock structure, including common stock with $0.01 par value, and provides formal exhibits for earnings releases, presentations, transition agreements, and other material corporate updates.
CONMED Corp director David M. Bronson reported compensation-related equity activity. On June 2, 2026, he exercised 668 restricted stock units into the same number of common shares, bringing his direct common stock holdings to 17,909 shares.
On June 1, 2026, he received a new award of 5,772 RSUs under CONMED’s 2025 Long-Term Incentive Plan. Each RSU represents a contingent right to one share of common stock and generally vests 100% after one year. These transactions are reported as grants and derivative exercises rather than open-market buys or sells.
CONMED Corp director LaVerne H. Council reported compensation-related equity activity. On June 2, 2026, Council exercised 668 RSUs into the same number of common shares, bringing direct common stock holdings to 4,716 shares after the transaction. There were no open-market purchases or sales.
On June 1, 2026, Council received a grant of 5,772 RSUs under CONMED’s 2025 Long-Term Incentive Plan. Each RSU represents a contingent right to receive one share of common stock and is generally scheduled to vest 100% after one year, aligning the director’s compensation with future company performance.
CONMED Corp director Kim Kelderman received a grant of 5,772 restricted stock units (RSUs) as equity compensation. Each RSU represents a contingent right to receive one share of CONMED common stock under the company’s 2025 Long-Term Incentive Plan.
The RSUs generally vest 100% after one year, aligning Kelderman’s compensation with shareholder interests over that period. Following this award, Kelderman holds 5,772 RSUs directly, which may convert into the same number of common shares if the vesting conditions are satisfied.
CONMED Corp director Charles Farkas reported routine equity compensation activity. On June 1, 2026, he received a grant of 5,772 RSUs, each representing a right to one share of common stock under the Company’s 2025 Long-Term Incentive Plan, generally vesting 100% after one year. On June 2, 2026, he exercised 668 RSUs into the same number of CONMED common shares at a stated price of $0.00 per share, bringing his direct common stock holdings to 15,527 shares. After the exercise, the specific 668-unit RSU award shows no remaining balance, while the newer 5,772-unit grant reflects his continuing derivative position.
CONMED Corp director Mark Kaye reported equity compensation activity, not open-market trading. He received an award of 5,772 restricted stock units (RSUs), each representing a contingent right to one share of CONMED common stock under the company’s 2025 Long-Term Incentive Plan, generally vesting 100% after one year.
On a separate line, 668 RSUs were converted into 668 shares of common stock at a stated price of $0.00 per share, reflecting the non-cash nature of this compensation. Following this exercise, Kaye directly holds 820 shares of common stock and retains 5,772 unvested RSUs scheduled to vest after their one-year period, subject to plan terms.
CONMED Corp director Barbara J. Schwarzentraub reported equity compensation and a routine option-like exercise. She received 5,772 RSUs on June 1, 2026, each representing a contingent right to one share of common stock under the 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after one year. On June 2, 2026, 668 RSUs were exercised and converted into 668 shares of common stock, leaving her with 5,012 shares of common stock held directly. A separate line shows 1,442 shares of common stock held indirectly by The Barbara J. Schwarzentraub Trust.
CONMED Corporation’s interim corporate controller and principal accounting officer, Kimberly Lockwood, reported her existing equity holdings. She directly holds 1,868 shares of common stock, along with multiple grants of restricted stock units and stock options that provide potential future rights to additional common shares.
The RSUs each represent a right to receive one share of CONMED common stock, generally vesting over a three‑year period under the company’s 2025 Long-Term Incentive Plan. The stock options were granted under CONMED’s 2015 and 2018 Long-Term Incentive Plans and typically vest evenly over five years, with exercise prices ranging from $58.33 to $144.55 per share and expirations between 2028 and 2035.
CONMED Corp reported initial holdings for Kimberly Lockwood, Interim Corporate Controller and Principal Financial Officer. The Form 3 shows direct ownership of 1,868 shares of common stock and multiple equity awards granted under the company’s long-term incentive plans.
Lockwood holds RSUs covering 2,838 and 2,839 underlying shares of common stock, which generally vest over three years under the 2025 Long-Term Incentive Plan. She also holds several option grants on common stock, with exercise prices ranging from $58.33 to $144.55 per share and expiration dates between 2028 and 2035, typically vesting in equal installments over five years.
CONMED Corporation entered into a First Omnibus Amendment to its existing credit documents to add a new $450 million senior secured delayed draw Term A-2 Loan Facility. This facility is available in a single draw through June 14, 2026 and matures on June 10, 2030, matching CONMED’s existing revolving and term loans.
The company plans to use the Term A-2 proceeds to repurchase a portion of its outstanding 2.25% Convertible Senior Notes due 2026 and to pay related fees and expenses. Interest on the new loans will be based on adjusted term SOFR plus a margin of 1.125%–2.25% or a base rate plus 0.125%–1.25%, tied to CONMED’s consolidated senior secured leverage ratio, with initial margins of 1.75% for SOFR loans and 0.75% for base rate loans.
CONMED Corporation reports several governance updates. The board will expand to nine directors and has appointed Celine Martin and Jeff Mirviss as independent directors effective July 1, 2026, with committee assignments across audit, strategy, compensation, and governance. The board also named Kimberly Lockwood interim Corporate Controller and interim Principal Accounting Officer effective June 1, 2026.
Amended and restated bylaws update advance notice rules, including a 90–120 day window for 2027 annual meeting nominations and proposals, with notices due between January 18 and February 17, 2027. At the May 18, 2026 annual meeting, stockholders elected seven directors, approved the advisory vote on executive compensation, and ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal 2026.